Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is a leading pure-play in mRNA capping and viral clearance assessment and while the current valuation likely limits downside, the firm’s Neutral view is based on its call that there are “more attractive categories within the bioprocessing subsegment.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences chairman Carl Hull to retire, R. Andrew Eckert to succeed
- Maravai LifeSciences Appoints New Chairman Amid Leadership Transition
- Maravai Lifesciences downgraded to Sell from Neutral at Goldman Sachs
- Maravai Lifesciences initiated with a Peer Perform at Wolfe Research
- Maravai Lifesciences price target lowered to $7 from $10 at Morgan Stanley